-
Mashup Score: 0Upadacitinib Demonstrates Higher Rates of Adverse Events Compared with Adalimumab in PsA - 6 month(s) ago
Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 7Comparison of Psoriatic Arthritis Therapies Finds Bimekizumab More Effective Than Guselkumab - 6 month(s) ago
A matching-adjusted indirect comparison found that some patients with PsA are more likely to achieve long-term treatment outcomes with bimekizumab.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 0
At week 52, investigators noted an overall improvement of 93% in PASI scores from baseline.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Improved Outcomes for Psoriatic Arthritis Patients with Less Than a Year Delay for Diagnosis - 7 month(s) ago
These data highlight the potential window of opportunity for PsA patients’ diagnoses and any patient characteristics of those with longer diagnostic delays.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Improved Outcomes for Psoriatic Arthritis Patients with Less Than a Year Delay for Diagnosis - 7 month(s) ago
These data highlight the potential window of opportunity for PsA patients’ diagnoses and any patient characteristics of those with longer diagnostic delays.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Nationwide Study Highlights Infection Risk Levels for PsA Patients on Different Treatments - 7 month(s) ago
These data on patients with psoriatic arthritis point to risk levels for new adalimumab users as well as users of ustekinumab and etanercept.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Impact of Psychosocial Factors Highlighted Regarding Psoriatic Arthritis Joint Pain - 7 month(s) ago
The findings in this research letter allow for greater understanding of residual joint pain modulators, with the overall goal being to improve health outcomes for those with PsA.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Nationwide Study Highlights Infection Risk Levels for PsA Patients on Different Treatments - 7 month(s) ago
These data on patients with psoriatic arthritis point to risk levels for new adalimumab users as well as users of ustekinumab and etanercept.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Guselkumab Improves Pain, Physical Function in Patients with Treatment-Resistant PsA - 7 month(s) ago
A real-world cohort of patients with treatment-resistant active psoriatic arthritis receiving 6 months of guselkumab treatment achieved clinically meaningful improvements in pain and physical function.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 14Increased vascular inflammation on PET/CT in psoriatic arthritis patients in comparison with controls - 9 month(s) ago
Background Patients with psoriatic arthritis (PsA) have an increased risk of cardiovascular disease, possibly due to a chronic inflammatory state. Objectives The main objective of this study was to investigate the difference in vascular inflammation, measured with 18-fluorodeoxyglucose positron emission tomography/CT (PET/CT), in PsA patients and controls. We conducted a secondary analysis to assess the association between clinical parameters of disease activity with vascular inflammation in PsA. Methods We included a total of 75 PsA patients with active peripheral arthritis (defined as ≥2 tender and swollen joints) from an ongoing clinical trial (EudraCT 2017-003900-28) and a retrospective group of 40 controls diagnosed with melanoma, without distant metastases and not receiving immunotherapy. The main outcome measure was aortic vascular inflammation which was measured on PET/CT scans using target-to-background ratios. Clinical disease activity in PsA was assessed with joint counts, b
Source: rmdopen.bmj.comCategories: General Medicine News, RheumatologyTweet
Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab among patients with #PsoriaticArthritis. https://t.co/2WRAgxxx2r